Disclaimer: All information on this section is of a general nature.
Before making any investment decision, you should consult your adviser.
Recce Ltd (ASX: RCE) - Ahead of schedule for Phase 1 human tests
Since listing in January 2016, in-vitro and animal cell testing has demonstrated the antibiotic as well as anti-cancer (and most recently anti-viral) properties of RCE’s patented, synthetic-polymer RECCE® antibiotics. Tests have also indicated the drugs’ efficacy without toxicity (including genetic toxicity).